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Pancreasand IsletTransplantationWell, I Wouldn’t be Any Worse Off, Would I, Than I
am Now? A Qualitative Study of Decision-Making,
Hopes, and Realities of Adults With Type 1
Diabetes Undergoing Islet Cell Transplantation
Jane Speight, PhD,1,2,3 Alison J. Woodcock, PhD,4 Matthew D. Reaney, MSc,1 Stephanie A. Amiel, MD,5
Paul Johnson, MD,6 Neil Parrott, MD,7 Martin K. Rutter, MD,8,9 Peter Senior, PhD,10 James A.M. Shaw, PhD11
Background. For selected individuals with type 1 diabetes, pancreatic islet transplantation (IT) prevents recurrent severe hypo-
glycemia and optimizes glycemia, although ongoing systemic immunosuppression is needed. Our aim was to explore candidates
and recipients' expectations of transplantation, their experience of being on the waiting list, and (for recipients) the procedure and
life posttransplant. Methods. Cross-sectional qualitative research design using semistructured interviews with 16 adults (8
pretransplant, 8 posttransplant; from 4 UK centers (n = 13) and 1 Canadian center (n = 3)). Interviews were audio-recorded, tran-
scribed, and underwent inductive thematic analysis.Results. Interviewees were aged (mean ± SD) 52 ± 10 years (range, 30-64);
duration of diabetes, 36 ± 9 years (range, 21-56); 12 (75%) were women. Narrative accounts centered on expectations, hopes,
and realities; decision-making; waiting and uncertainty; the procedure, hospital stay, and follow-up. Expected benefits included
fewer severe hypoglycemic episodes, reduced need for insulin, preventing onset/progression of complications and improved psy-
chological well-being. These were realized for most, at least in the short term. Most interviewees described well-informed, shared
decision-making with clinicians and family, and managing their expectations. Although life “on the list” could be stressful, and im-
munosuppressant side effects were severe, interviewees reported “no regrets.” Posttransplant, interviewees experienced in-
creased confidence, through freedom from hypoglycemia and regained glycemic control, which tempered any disappointment
about continued reliance on insulin.Most viewed their transplant as a success, though several reflected upon setbacks and hidden
hopes for becoming “insulin-free.”Conclusions. Independently undertaken interviews demonstrated realistic and balanced ex-
pectations of IT and indicate how to optimize the process and support for future IT candidates.
(Transplantation Direct 2016;2: e72; doi: 10.1097/TXD.0000000000000581. Published online 21 April 2016.)Received 16 October 2015. Revision requested 6 February 2016.
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2 Transplantation DIRECT ■ 2016 www.transplantationdirect.comType 1 diabetes (T1D) is an autoimmune condition char-acterized by absolute insulin deficiency caused by immu-
nological damage to theβ cells in the pancreas. It can occur at
any age but approximately half of cases are diagnosed in chil-
dren and adolescents. Acutely, the immediate life-threatening
consequences of insulin deficiency are managed with exog-
enous insulin, delivered by multiple daily injections or an
insulin pump. Thereafter, effective daily blood glucose
management is critical to avoid both acute complications
(eg, severe hypoglycemia, diabetic ketoacidosis) and long-
term complications (eg, microvascular disease of the kidneys,
eye, and nerves; ischemic heart disease, cerebrovascular dis-
ease, peripheral vascular disease). Thus, the reality of living
with T1D is a challenging and relentless daily burden involv-
ing continual attention to blood glucose management, with
titration of insulin doses, according to food intake and physi-
cal activity, and self-monitoring of blood glucoses levels. Sus-
ceptibility to severe hypoglycemia increases with age and
duration of T1D,1 and the ability to recognize warning symp-
toms (“awareness”) of hypoglycemia diminishes placing the
person at a 6-fold increased risk of severe hypoglycemia.2
Currently, successful β cell replacement through whole
pancreas or isolated islet cell transplantation (IT) is the only
therapy that offers a minimally invasive procedure, which
optimizes glycemia reproducibly, with absolute prevention
of recurrent severe hypoglycemia, and restoration of hypogly-
caemic warning signs.3 Since the seminal success in Edmonton,
Canada,4 more than 1000 people with T1D have received
deceased donor pancreatic islet allografts worldwide.5 Al-
though safer and less invasive than whole pancreas trans-
plantation,6 there is attrition in graft function over time;
at least 50% of transplant recipients return to insulin injec-
tions by 5 years.7,8 A strict ongoing systemic immunosup-
pression medication regimen is required to minimize
likelihood of rejection of the transplanted islet cells. Thus,
recipients need to remain vigilant for signs of graft failure,
and frequent clinic appointments and regular blood glu-
cose self-monitoring remain the norm posttransplant.9
Some commentaries have raised concerns about whether
current benefits of IT truly outweigh the risks.10,11 Further-
more, the paucity of data on recipients' expectations and sat-
isfaction has been highlighted by both the US Agency of
Healthcare Research and Quality12 and UK National Insti-
tute for Health and Clinical Excellence.13 Increasingly, the
success of biomedical interventions is assessed not only in
terms of biomedical outcomes (such as those noted above)
but also in terms of their impact on psychological or
“patient-reported” outcomes. Our systematic review found
that IT potentially improves psychological well-being,
diabetes-specific quality of life, fear of hypoglycemia, and
generic health status.14 However, we concluded that
existing questionnaires are unlikely to capture fully the im-
pact and experience of undergoing IT, because they are not
necessarily designed or selected to reflect the full experi-
ence for the person with T1D.14 If risks and benefits of
IT are to be fully understood, a truly person-centered ap-
proach is needed to understand the individual's full experi-
ence of the IT process, and optimize positive impact for
recipients. This is missing from published literature.
Only 2 qualitative studies have previously explored the ex-
periences of IT recipients. The first was outlined briefly in an
article focused almost entirely on quantitative outcomes.15The second was also a mixed methods study, and demon-
strated both the positive impact of IT on personal control
over social life situation, and the recipients' experience of IT
as worthwhile.16 To our knowledge, no study to date has ex-
plored expectations and the process of undergoing IT from
the individual's perspective. Thus, our aim was to explore
the expectations of people undergoing IT, how they weighed
up advantages and disadvantages during the decision-
making process, their experiences of being on the waiting list,
the procedure itself and life posttransplant.MATERIALS AND METHODS
Participants
All IT candidates and recipients at 4 UK transplant centers
(King's, Manchester, Newcastle, and Oxford) were invited to
participate. Strict selection criteria for the UK IT program in-
cluded: 2 episodes or more of severe hypoglycemia requiring
third-party intervention over 2 years and impaired hypogly-
cemia awareness (Clarke questionnaire17 score ≥4), despite
optimized conventional diabetes therapy. Risks and benefits
of the procedure including alternative interventions were
discussed with all potential transplant candidates, and all
were assessed by a clinical psychologist before transplanta-
tion, with the main aim of identifying those who might re-
quire additional posttransplant support.
Due to the small numbers of UK transplants conducted at
that time, and to gain an international perspective, a purpo-
sive sample of 6 participants was recruited from Edmonton,
Canada: 3 pretransplant and 3 posttransplant, considered
by their clinicians to have experiences that would enrich
our study. Criteria for accessing the Canadian IT program
were similar to the United Kingdom.
Posttransplant, immunosuppression therapy comprised
tacrolimus/sirolimus or tacrolimus/mycophenolate mofetil.
Interview Schedule
Using a semistructured interview schedule, we invited par-
ticipants to explore their expectations and experiences in re-
sponse to the following open questions: What did your
doctor tell you to expect from your transplant? How much
were you involved in decidingwhether or not to have this sort
of transplant? How do you feel about your transplant now?
Posttransplant respondents were also asked: How satisfied
are you with your transplant? Has the transplant met your
expectations? If so, in what ways? Can you tell me about
the immunosuppression drugs that you have to take?
Procedure
The UK Medical Research Ethics Committee gave ethical
approval, with site-specific approvals at each UK center; the
University of AlbertaHealthResearch Ethics Board–approved
interviews at Edmonton. Each participant provided informed
written consent.
In the United Kingdom, interviews were conducted in the
diabetes centers by 2 psychologists (rotating between J.S.,
A.W., and M.D.R.), all experienced in diabetes research
and independent of the transplant teams. Two of the 13 par-
ticipants were interviewed at home, accompanied by their
husbands. For logistical reasons, interviews with partici-
pants based in Edmonton were conducted by telephone
or “Skype.” Interviews typically lasted 90 minutes though
TABLE 1.
Participants' demographic and clinical characteristics
(N = 16)
N or Mean ± SD
Age, y 52 ± 10 (range, 30-64)
Women-men 12: 4
Marital status Married/cohabiting 13
Single 2
Divorced 1
Ethnicity White 16
Duration of diagnosis, y 36 ± 9 (range: 21-56)
Transplant status Pre-ITA 7
Pre-IAK 1
Post-ITA 8
Transplant centre; transplant status Kings 4; all post-ITA
Manchester 4; all pre-ITA
Newcastle 3; 2 pre-ITA; 1 pre-IAK
Oxford 2; all post-ITA
Edmonton 3; 1 pre-ITA; 2 post-ITA
No. infusions (post-ITA only) One 2
Two 2
Three 3
Four 1
Current treatment Multiple daily injections 8
Insulin pump 8
Insulin-free 0
IAK, islet after kidney; ITA, islet transplant alone.
© 2016 Wolters Kluwer Speight et al 3half of that time explored quality of life (not presented here).
All interviews were digitally audio-recorded and transcribed,
though 3 ‘Skype’ recordings were of poor quality, so those
participants' data were subsequently excluded.
Analysis
We used inductive thematic analysis and extracted quotes
to illustrate themes. In contrast to deductive thematic analy-
sis, where hypotheses are imposed upon the data, in inductive
thematic analysis, the data are relied upon for generating the
structure of the findings.18 This is the ideal approach when
exploring new topics. Inductive thematic analysis involves
several phases: familiarization with the data, generating ini-
tial codes, searching for themes among codes, defining and
reviewing themes to produce a final structure. A “theme”
constitutes a pattern of explanation given by more than 1 in-
terviewee. Thematic analysis has been described as a tool that
underpins several qualitative research methods, such as
grounded theory and interpretative phenomenological analy-
sis but is free from the theoretical constraints and assump-
tions imposed by those methods.18 More recently, thematic
analysis has been considered as a valuable method in its
own right.19
In the first stage, between interviews, 1 psychologist (M.D.
R.) read each transcript and proposed themes for each partic-
ipant, making notes about codings.20 These were discussed
by all 3 psychologists. In the second stage, 1 psychologist
(A.W.) read repeatedly all transcripts and notes, together
constituting the data corpus. At the end of thematic analysis,
after repeated reading of the data corpus, no new themes
were emerging. In the final stage, further checks (by J.S. and
M.D.R.) confirmed no additional recurring themes.
An anonymized coding system—identity number (X), sex
(M/F), transplant status (pre/post), country (UK/Canada)—
is used to identify the source of each quote (in parentheses af-
ter each quote). Study center was excluded to preserve inter-
viewee anonymity. Because most physicians were male and
most transplant co-ordinators female, participants' quotes
were modified so that all physicians are referred to as males
and all co-ordinators as females. Thus, professionals' ano-
nymity is preserved in the case of exceptions to this rule.RESULTS
Table 1 summarizes the characteristics of the 16 partici-
pants (13 from the United Kingdom, 3 fromCanada). Twelve
were women, all were white, and 13 were married/
cohabiting. The mean age of interviewees was 52 years,
and they had been living with T1D for a mean of 36 years.
Eight were interviewed pretransplant and 8 posttransplant,
of whom most had received at least two separate infusions
of islet cells. Half of the participants were using an insulin
pump. Of the posttransplant interviewees, none was
insulin-free at the time of interview.
Expectations, Hopes and Realities of IT
Research Participation: Excitement and Altruism
Interviewees described involvement in the transplant pro-
gram as exciting, “a medical adventure because it's research”
(9FpostUK), or expressed altruistic sentiments, “I did hope
that, even if it didn't work on me, that… it might help some-
body else” (12FpostUK) (Table 2).Fewer “Hypos”, Better Awareness and “Better Control”
Candidates were clear about why they wanted the trans-
plant. Their reasons included recurrent unpredictable severe
hypoglycemia (“hypos” or “lows”) and impaired awareness
of hypoglycemia, which limited their quality of life; they re-
ferred to wanting “better control” or “greater stability” of
blood glucose. Food and insulin impacted unpredictably on
their blood glucose levels pre-IT. Post-IT, severe hypoglyce-
mia was reduced or eliminated, at least short term, and
awareness of hypoglycemia regained. However, the benefits
did not endure for everyone. The earliest recipient inter-
viewed had received 3 infusions but was experiencing fre-
quent hypoglycemia again.
Reduced Need for Injected Insulin: “No Guarantees”
Interviewees were accustomed to injecting insulin, and
most did not object to continuing to do so. Becoming
insulin-independent was a pre-IT hope often tempered by re-
alism and “no guarantee” clauses, which endured post-IT.
Nonetheless, some retained hidden hopes to become insulin-
independent and others had high expectations of “not having
hypos, not being on insulin, being able to eat more or less
what I wanted… everything about life would be better”
(12FpostUK). The idea of the transplant “working”was tied
up with hopes of insulin-independence. Even a small chance
of an insulin-free period, no matter how short, went into
the decision-making equation, even if it was then rejected
as unrealistic.
Post-IT, some had been temporarily insulin-free, although
all were using insulin pumps or injections when interviewed.
They could be “disappointed” or “upset,” particularly if de-
nied another transplant, yet spoke of support from the
TABLE 2.
Expectations, hopes, and realities
Sub-theme Candidates’ (pretransplant) reports Recipients’ (posttransplant) reports
Fewer ‘hypos’, better awareness
and ‘better control’
“Not having the feeling of the hypo, the warning of the hypo,
that is worrying… It’ll stop the hypos. I think … not having
hypos is worth everything else, it really is” (3FpreUK)
“My life was made very unpleasant by hypos … I didn’t realise
how appalling until it stopped. I couldn’t quite believe the
difference … For the first time ever, I feel in control of the
diabetes rather than the diabetes controlling me” (9FpostUK)
“The hypos seem to be considerably less in people that have
had them [transplants]. In which case, that would help
me” (5FpreUK)
The last major hypo I had was the day before my first transplant”
(13MpostUK)
“Benefits would be stability, because that’s what I was lacking,
the stability, and being unable to detect the low blood
sugars” (16FpostCan)
Reduced need for injected insulin:
“no guarantees”
“[The] transplant will not guarantee that I’ll be insulin-free
and, you see, that doesn’t bother me” (3FpreUK)
“[I] was told that there was a possibility that I would come off
injecting. I thought, ‘I’m not going down that line’. I just
thought, ‘No, I think not somehow’… and I think I went
along that route because I just think it’s a more rational
route” (9FpostUK)
Hopes? It would work and I wouldn’t need insulin any more.
I think that’s probably a bit unrealistic… there’s no 100%
guarantee is there?” (5FpreUK)
“Yeah, I was upset. But I had plenty of support [from named
doctors]” (11FpostUK)
“The best I can hope for is that, um, the islets work and I
maybe only need a very small dosage of insulin, but
we’re both realistic insofar as we both doubt very
much that I’ll come off insulin” (6FpreUK)
“I wasn’t even told that I would probably be able to come off
insulin. I asked the question and they said, ‘It’s unlikely’. Now,
they did it deliberately probably. They might have hoped that it
could but they were certainly not intending that it shouldn’t
happen.” [Posttransplant:] “I was incredibly disappointed
and then I thought, this is daft, why are you depressed? …
What am I worried about? No major hypos, stabilisation of
complications, they’re the most important things” (13MpostUK)
“I think I was just disappointed. I was, you know, wanting the ability
to stay off insulin but, again, if I still had the [blood glucose]
control, taking needles wasn’t the problem” (16FpostCan)
Serious risks to immediate
and long-term health
Swollen ankles, mouth ulcers, impaired liver function, impaired
kidney function, headaches, tiredness… One wonders why
I want to have it in the first place. But he is preparing me
with statistics” (2FpreUK).
“I must have some lucky guardian angel because, you know,
I didn’t get anything, apart from a couple of colds, really
it was luck I think, you know” (9FpostUK)
“There's 70% more chance of getting cancer, kidney problems,
but they’ve not had that happen so far, … and everyone’s
got a chance of getting these things. I worried at first but not
now … I figured other people have had it and they’re
taking the drugs… I don’t dwell on it because if it’s going
to happen, it’s going to happen” (8FpreCan)
“I kept saying ‘I won’t get mouth ulcers. I won’t get anything’, and
I didn’t” (12FpostUK)
“The only risk actually was from the drugs; the risk of the process
itself is so minimal … and when I tried to get them to tell me,
you know, out of 10 what are the risks…, it was difficult
for them, and I shouldn’t perhaps have tried to force it. But
take for instance, the risk of developing skin cancer or
remaining on anti-rejection drugs, um they can’t say that it’s
you know 10% more than it was before or 20% more. I mean
it’s ridiculous. All they can say is it’s an added risk, a real
risk” (13MpostUK)
“The first lot of tablets, they were really making my mouth
sore…. very loose bowels, which is very, quite daunting,
especially when you’re working” (14FpostUK)
“They switched my immunosuppressants quite a few times…
I had intense side effects” (16FpostUK)
4 Transplantation DIRECT ■ 2016 www.transplantationdirect.comtransplant team and how they reframed their disappointment
to focus on outcomes achieved, for example, fewer severe
hypoglycaemic events, blood glucose stability.“Not Being Diabetic”
Interviewees expressed the hope that having IT would
mean they no longer had diabetes: “I'd be nondiabetic for a
time… I would welcome the break… I'm very aware that at
best I might get 5 years, and then …be diabetic again, but…all the rest of it would be marvellous” (2FpreUK). Indeed,
1 posttransplant interviewee had declared to the UK Driving
and Vehicle Licensing Authority that she no longer had dia-
betes but had to reverse that when the need for exogenous in-
sulin returned.Preventing or Halting Complications
Interviewees mentioned that pre-IT, they had hoped the
transplant would have the benefit of preventing or halting
© 2016 Wolters Kluwer Speight et al 5progression of complications, particularly retinopathy.
In the single case of islet after kidney, the interviewee
indicated that the clinician was hoping “to protect
my kidney for as long as possible”. Posttransplant, the
only person who mentioned complications said that his
had stabilized.Benefits for Psychological Well-Being
The hopes of almost all IT recipients were realised, initially
at least, with noticeably improved psychological well-being
and energy: “I actually had energy… I didn't feel so irritable”
(9FpostUK). Another commented, “not embarrassing your-
self at work or [with] friends, you know. That always both-
ered me… I don’t have any problems with lows right now.
So, yes, more confidence and less worries” (15MpostCan).Serious Risks to Immediate and Long-Term Health
Overall, risks were less clearly recalled and described than
benefits and were often considered unlikely. For people sev-
eral years post-IT, the risks seemed to have passed. Inter-
viewees were aware of, and some were fatalistic about, the
possibility of immunosuppressant side effects. After a num-
ber of straightforward infusions, interviewees tended to place
more emphasis on risk of side effects than on the procedure.
Side effects ranged from severe, “I lost the end of my tongue
actually from a terrible ulcer” (10FpostUK), to minor, “a
couple of infections” or none, in which case, participants de-
scribed themselves as “lucky” or having willpower.TABLE 3.
Decision-making pre-transplant and dealing with risks posttrans
Sub-theme Candidates’ (pretransplant) reports
Informed decision-making “Yes, I realise that the anti-reduction, rejection drugs can b
um, and I think they stressed that, possibly over stresse
I can see why they’ve done it because you don’t want s
afterwards saying, ‘Well, you didn’t tell me about this a
didn’t tell me’…they’ve been very, very open about the
that could happen” (3FpreUK)
“Realistically, at the end of the day, it’s always going to be
choice, isn’t it?” (4MpreUK)
“It sounds exciting - anything that helps hopefully is going
but you need to be more informed about everything don
But I’m willing to learn everything I can” (5FpreUK)
Involving others in
the decision
“I speak to my husband, and… I don't know if I would inv
children. I don't think it's probably fair… they’re concer
but they also want the best for me” (2FpreUK)
“Well I spoke to my son and he said, ‘There’s risks with e
He’s saying, ‘Go for it, just go for it!’ and I said, ‘Well, y
want to, but I’m only trying to think of what the minus i
You’d be a fool not to, wouldn’t you really? You have to
of that but on the whole… it sounds good” (5FpreUK)
Balancing risks
against benefits
“If you thought that would happen, you wouldn't have it in
place. You hope it won't happen to you” (2FpreUK)
“it’s like everything, what affects one won’t affect another.
anything can go wrong, but … I don’t think anything is
its risks, um, and I do believe if it’s going to happen, it’
to happen, whatever it is” (3FpreUK)
“I don’t want to get cancer but… I can’t let it stop me” (8Decision-Making Pretransplant and Dealing With
Risks Posttransplant
Informed Decision-Making
Clinical teams were reported as being “very open about
the things that could happen” (3FpreUK), describing the
risks fully, although this could be seen as a necessary strategy
to avoid comeback. Although some could not see the point
of receiving detailed information early on, before “suitability”
was established, others were determined to seek all available
information to make “an informed decision”. Interviewees
emphasized that the decision was theirs (Table 3).
Involving Others in the Decision
Family involvement in decision-making varied: most
discussed it with family but some had already decided with
their clinician. Typically, individuals had to temper their
own and their family's enthusiasm.
Balancing Risks Against Benefits
Focusing largely on the transplant itself, interviewees bal-
anced perceived benefits against risks, with some wishful
thinking. Earlier UK IT recipients recalled the lack of cer-
tainty clinicians had expressed about the risks involved, leav-
ing them worried, partly due to the novelty of the procedure.
Once they had decided on IT, coping strategies served to re-
duce anxiety: interviewees tended to “think on the positive
side” or consider risks as a matter of chance or fate, which
did not worry them; they commonly put risks to one side;
or they managed expectations, believing the worst that couldplant
Recipients’ (posttransplant) reports
e nasty,
d it, but
omebody
nd you
things
my
to be good,
’t you?
olve
ned,
“We made a decision as a family… to say yes this should improve
things for all of us” (10FpostUK)
verything’…
es, I do
s on it.’
think
“It was very much a joint decision to my wife and me” (13MpostUK)
“Together (my endocrinologist and myself ) we made the decision.
Then… he gave me what I needed to know and for me to go
home to my family” (16FpostCan)
the first “Yes, there are obviously risks. There are risks to everything. You
walk across the road it’s a risk, isn’t it?” (9FpostUK)
Well,
without
s going
“When I tried to get them to tell me, you know, ‘Out of 10, what
are the risks, developing this or that?’, it was difficult for
them” (13MpostUK)
FpreCan)
“There wasn’t really a lot of information, um, on the procedures …
its been done, you know, four times before” (14FpostUK)
6 Transplantation DIRECT ■ 2016 www.transplantationdirect.comhappenwas that the procedure did not “work,” and conclud-
ing “Well, I wouldn't be any worse off, would I, than I am
now?” (5FpreUK). Post-IT, after a number of straightfor-
ward infusions, recipients emphasised the risk of the immu-
nosuppression side-effects rather than the procedure.
With regard to ongoing immunosuppression required
post-IT, the reality was that some experienced health prob-
lems. However, none of the candidates or recipients spoke
of it in terms of swapping 1 treatment (insulin) for another
(immunosuppression). Even those who had experienced sev-
eral setbacks reflected that there was no permanent damage:
“I tried something and it didn’t work and that’s pretty much
it” (16FpostCan).Waiting and Uncertainty
Pre-transplant Investigations: Not Building up
Your Hopes
During pre-IT investigations, participants did not want to
build up their hopes. The time commitment for pre-IT inves-
tigations was considerable and this extended period of uncer-
tainty could be stressful (Table 4).
On the Waiting List: “Is the Phone Alright?”
The wait for a suitable donor was often lengthy, stressful
and limited interviewees' ability or willingness to travel.
Post-IT interviewees described this as the most difficult part,TABLE 4.
Waiting and uncertainty
Subtheme Candidates' (pretransplant) reports
Pretransplant investigations:
not building up your hopes
“… if I am the recipient, um, because I don’t think it
does to build your hopes up too much. I shall be ve
very disappointed if I’m not. But if I’m not,
‘so be it’, you know” (3FpreUK)
“The decision isn’t really made insofar as, there’s still
work that’s got to be done, um, different tests to d
I could fall at any one of those hurdles” (6FpreUK)
On the waiting list: ‘Is the
phone alright?’
False alarms
After transplant: ‘It’s in
the lap of the Gods’becoming increasingly anxious when there was no call from
the centre.
False Alarms
When the call came, the islet preparation could prove un-
suitable. Participants experienced at least one false alarm,
which could be “upsetting” or depressing.
After Transplant: “It's in the Lap of the Gods”
Even when the transplanted islets produced insulin, there
remained uncertainty about the future, whether they would
remain insulin-independent and whether or not subsequent
transplants would be needed.The Procedure, Hospital Stay and Follow-Up:
“No Regrets”
Pretransplant interviewees thought they had a clear under-
standing of the procedure and described it in their ownwords
(Table 5).
When the procedure went well, it was mostly described as
quick, pain-free and unproblematic: “it took half an hour,
and that was extraordinary” (9FpostUK). However, some
experienced “painful” complications.
Recovery was usually swift but when the procedure was
not straightforward, hospital stays were longer than ex-
pected. In the United Kingdom, because it was a novelRecipients' (posttransplant) reports
ry,
“I think it would be nice to sort of hurry up the investigations and stuff,
because it takes like 3 months, and you’re wondering… if you’re
going to be listed and stuff… I didn’t realize it would take so long [Then,
waiting for 2nd infusion:] They seem to be more on top of it now and
said, you know, ‘We’ll get you in for your bloods Monday because we
don’t want to keep you waiting” (11FpostUK)o.
“They tried to make it as simple as possible but … there are probably
10 different times you had to come in for a certain test or something
like that. So, I would estimate about 10 times and then the wait for
the transplant” (16FpostCan)
“[Waiting…] was almost the worst bit because, you’re completely on edge
the whole time and every phone call at a weird time you think, ‘Oh God,
that could be it.’” (10FpostUK)
“Every time the phone went I expected it to be the hospital… I missed my
son’s graduation… I had to cancel holidays” (13MpostUK)
“[I waited about…] 6 to 8 weeks I think. It seemed like quite a long time at
the time. I was like, ‘No-one’s ringing, no-one’s ringing! Is the phone
alright?’” (14FpostUK)
“I got one… a call, just before Christmas, to go up. I was up there the
whole day and it wasn’t suitable for me at the end of the day, so
that was quite an upsetting sort of issue” (11FpostUK)
“You get all hyped up, you’re there and ready to go and the next thing,
you’re all fixed up with your IVs and they say, sorry, you’re not getting
it this time, the cells aren’t good enough, there weren’t enough cells
and it was kind of a low period for a while there” (15MpostCan)
“They may want to do a third transplant, they might not, I don’t know,
because I don’t know what’s going to happen to these hormones …
I mean, I don’t know… it’s just, it’s in the lap of the gods” (9FpostUK)
TABLE 5.
The procedure, hospital stay, and follow-up
Subtheme Candidates' (pretransplant) reports Recipients' (posttransplant) reports
‘No regrets’ “The islets will be injected into my liver… I think, is it the portal
bit that goes into the liver? Anyway… I know it’s going to be
done under local [anaesthetic]… I don’t know how long it’s
going to take, um, I’m presuming it’s going to be drip fed in
at a controlled rate… and I know it’s going to be done in the
X-ray department so that they can see … I think [the cells]
sit in the liver and they work in the liver” (6FpreUK)
“The second procedure took an hour and a half, um, because it was more difficult to get the
actual tube into the portal vein… and I thought ‘this could be a new form of torture’ …
I felt pretty fragile for a day and then I began to perk up no end” (9FpostUK)
“It was really painful to breathe, because something had happened with my lungs, um,
so um, I was on morphine and things that week, but the ones after that were
absolutely fine” (10FpostUK)
“It didn't hurt me; it wasn't painful; there was nothing unpleasant about any of it”
(12FpostUK)
“I had some problems right after the transplant. I was in hospital for a week. It wasn’t a
happy time for me… I thought I’d just have the transplant and be home in a day
or so” [Post-IT check-ups:] “I used to go three times a week two times a day… It was
very restrictive. First thing in the morning at 7 o’clock… then come back two hours
later, and they did that for three months” (15MpostCan)
“It was just the time commitment that I didn’t realise how extensive it would be. So, for me
that was the downside” [Following transplant failure:] “Still, although it’s a huge level of
disappointment, I have no regrets about trying it” (16FpostCan)
© 2016 Wolters Kluwer Speight et al 7procedure, the hospital stay was routinely longer than that in
Edmonton.
Posttransplant check-ups were a considerable commit-
ment, and particularly burdensome if living far away from
the centre. Some said they had not realized “how extensive
it would be” (16FpostCan).
Balancing the outcomes against immunosuppressant side
effects, the procedure and its eventual outcome, as well as
the time commitment, most reported “no regrets” about “go-
ing for it”.DISCUSSION
This is the first in-depth qualitative study investigating the
expectations and experiences of adults with T1DMundergo-
ing IT in the United Kingdom, without which meaningful
quantitative evaluation of IT is not possible. Although several
quantitative investigations have evaluated impact on health
and well-being,14 our study represents the first to explore ex-
pectations, hopes, decision-making, and outcomes in the re-
cipients' own words.
Although none of the post-IT participants were insulin-
free at the time of interview, insulin independence has never
been promoted actively as a goal of the UK islet transplant
program. All interviewees reported severe recurrent and un-
predictable hypoglycemia pretransplant and most expected
or hoped for modest improvements afterwards. Consistent
with published quantitative findings,14 this study confirmed
that, posttransplant, interviewees reported being pleased
with various combinations of improved glycemia, regained
awareness of hypoglycemia, and, most commonly, reduced
frequency or severity of hypoglycemia. This had “life-
changing” psychological benefits, improvingwell-being, con-
fidence, and quality of life.
Overall, in contrast to the post-IT participants (early recip-
ients), transplant candidates reported realistic expectations,
especially concerning “coming off insulin.” Physicians counsel
about this possibility pretransplant.10 Although transplant
teams largely managed expectations appropriately, many in-
terviewees retained hidden hopes (reportedly shared by somephysicians) of being among the minority to remain insulin-
free at 5 years. This natural tendency toward optimistic bias
needs to be recognized and managed by transplant teams.
Furthermore, recipients need support to develop strategies
to cope with disappointment at any stage, including not
being “suitable,” lengthy wait for donor organ, “false
alarms,” graft rejection, or function loss. Even though
transplant teams are now careful not to frame IT as a po-
tential cure, the lay belief endures, meaning that extra care
is needed to ensure that all professionals give the same cau-
tious message. It has been acknowledged elsewhere that indi-
viduals' goals and expectations impact on their perceptions
of IT success.10
Whether or not a period of insulin independence had been
experienced, coping with any disappointment when insulin
became necessary was addressed by reframing the benefits
to focus on blood glucose stability. A determination to re-
main positive, combined with the negative consequences of
transplantation, has been noted elsewhere.21,22 Whereas kid-
ney transplantation is life-saving and success is dichotomous
(ie, independence from dialysis or not), IT is life-changing
and offers several potential benefits. Thus, whereas coping
with disappointment and avoiding depression would be diffi-
cult for kidney transplant recipients,21 it may be easier for IT
recipients who can focus on other benefits.
Coping strategies were also apparent in participants' de-
scriptions of how they dealt with the uncertainty of life “on
the list,”with emphasis placed on luck, fate, chance, andwill-
power. Such observations have been made, where transplant
recipients used external loci of control to manage uncer-
tainties and organ rejection.23 Evidence from kidney trans-
plant research suggests that belief in chance or fate may be
a reasonable coping mechanism, because those with greater
perceptions of internal or personal control were most de-
pressed when the transplant failed.24,25
Given the realities of the transplant process, uncertainty
for those on the waiting list is unavoidable. Candidates need
to be prepared for the significant time commitment involved
in medical investigations. Pre-IT and post-IT investigations
need to be conducted efficiently, with appreciation that each
8 Transplantation DIRECT ■ 2016 www.transplantationdirect.comindividual balances this against personal commitments, in-
cluding family and employment. A successful transplant pro-
gram needs to prepare participants fully for the risks
involved—with sensitivity to how much information poten-
tial candidates may or may not want before their “suitabil-
ity” as a candidate is confirmed—both to physical health
and psychological well-being, and to detect problems and
provide support at any stage. Timely and efficient investiga-
tions, psychological assessments and a responsive clinical
team, who provide consistent messages, are key ingredients
for ensuring best possible care for IT recipients and their fam-
ilies during this time of high hopes and unavoidable uncer-
tainties. Our findings have informed the published Diabetes
UK patient guide,26 particularly ensuring that information
about risks of comorbidities and anticipated frequency of
hospital attendances are explicit.
Unsurprisingly, the decision to join the transplant waiting
list was made by the individual with support from, and infor-
mation sharing with, their clinical team. Family involvement
was actively encouraged but the individual decided when to
involve them and often needed to counter the families' enthu-
siasm by advocating information-seeking about the risks and
realities to reach a rational decision.
Our study has several limitations, particularly relating to
the sample. The UK sample size was small but included all
IT recipients and candidates (those on the waiting list) at
the time; the Canadian purposive sample was added to max-
imize confidence that UK experiences were similar to those in
a more established program. The selective and subjective
sampling of Canadian participants and the fact that several
recordings were of poor quality is a limitation. However,
we noted considerable heterogeneity of experience among
the Canadian participants, and their inclusion was only ever
intended to augment the sample size and validate the UK
experience, this being the main focus of the study. This
remains the largest qualitative study of IT conducted to
date. Qualitative studies cannot claim to be representative
but after repeated reading of the data corpus, no new themes
emerged, and we were satisfied that data saturation had
been achieved. We had a unique opportunity to under-
stand the experiences of IT recipients and candidates at
an early stage of the UK program. There was remarkable
commonality between the accounts of United Kingdom
and Canadian participants. This may be explained by the
fact that there is still a small number of IT centers, with
close collaboration and intercenter support internationally.
Although only half the participants were posttransplant,
which limits the findings about posttransplant status, there
was strength in this approach because the experience of being
on the waiting list was current for half the participants, not
relying on retrospection or subject to potential reframing.
The diversity of centers (4 United Kingdom and 1 Canada)
can be considered a strength, whereas the unintentional pre-
ponderance of whites and women raises some concerns for
generalizability. The IT program itself has a clear bias to-
ward female recipients, given the need for relatively low body
weight and modest insulin requirements. It is noteworthy
that the only other qualitative study also includes more
women than men.16 It is possible that IT recipients from
other ethnic groups may be more trusting and less willing
to ask questions, particularly if that might be viewed as
challenging authority.27Another limitation is that many early recipients had
achieved “celebrity status” in the diabetes world and, clearly,
all were grateful to their clinicians for the opportunity to be
among the first to receive an IT. Their many press interviews
may have led to some rehearsed responses and a certain reti-
cence to highlight any negative aspects of IT. Tomaximize the
likelihood of unfettered and balanced feedback, we used
3 strategies: (1) the psychologists who conducted the inter-
views were independent of the clinical centers and direct care
of the transplant recipients; (2) participants were assured of
anonymity, with any identifying words removed from the
quotes used; (3) we tapped into the participants' altruistic
tendencies and support for research by assuring them that
we were interested in any experiences/comments that would
help the centers to improve the islet transplant experience
for future recipients. Before joining the IT waiting list, pro-
spective candidates were screened for psychological stability,
meaning that extreme emotional reactions or unrealistic ex-
pectations were unlikely. Further research with a larger sam-
ple from the more established UK program, and considering
the longer-term outcomes, is now warranted to corroborate
or update these findings, especially since the introduction of
the new Diabetes UK patient guide to IT.26
This independently undertaken qualitative study sought to
capture the breadth and depth of experience of those under-
going IT. It provides insights into both common and individ-
ualistic expectations and experiences, offering clinicians the
opportunity to learn how to optimize the process, assess-
ment, and support for future IT candidates. The study also
provides a person-centered evidence base for developing
and selecting robust questionnaires for quantitative assess-
ment of patients' expectations, experiences and satisfaction
with IT, alongside biomedical outcomes.ACKNOWLEDGMENTS
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